Posted by Michael Wonder on 19 Sep 2024
ImCheck receives FDA fast track designation for ICT01 in combination with azacitidine and venetoclax in first-line acute myeloid leukaemia for patients unfit for induction chemotherapy treatment
18 September 2024 - ICT01, a humanised anti-butyrophilin 3A monoclonal antibody designed to selectively activate Vγ9Vδ2 T cells, has shown encouraging clinical data in acute myeloid leukaemia in its on-going Phase 1/2a EVICTION study.
ImCheck Therapeutics announced today that the US FDA has granted fast track designation to ICT01 in combination with azacitidine and venetoclax for the treatment of acute myeloid leukaemia patients 75 years or older, or who have co-morbidities that preclude use of standard intensive induction chemotherapy.
